What is Cytokinetics's finance lease, principal payments?

Cytokinetics (CYTK) reported finance lease, principal payments of $0 in Q1 2026.

How has Cytokinetics's finance lease, principal payments changed year-over-year?

Cytokinetics's finance lease, principal payments decreased by 100.0% year-over-year, from $202K to $0.

Cytokinetics CYTK Finance Lease, Principal Payments

Finance Lease, Principal Payments at other companies

Boston ScientificBSX

$0-100%

Other financials

Income statement

See full

Revenue$19.4M+1,126%

Operating income-$183.6M-18.0%

Net income-$206.0M-27.7%

EPS (diluted)-$1.67-22.8%

Balance sheet

See full

Cash & equivalents$129.8M+76.2%

Total debt$418.2M+75.8%

Total equity-$826.6M-210%

Total assets$1.3B+0.7%

Cash flow

See full

Operating cash flow-$145.5M-10.5%

CapEx$5.9M+4.7%

Free cash flow-$151.4M-10.3%

Valuation

See full

Market cap$10.7B+70.6%

Enterprise value$10.98B+70.7%

P/S101.1×-225×

Profitability

See full

Operating margin-605.1%-268pp

Net margin-784%-337pp

FCF margin-518.8%-223pp

Returns & leverage

See full

Return on equity-337.6%—

Debt / equity2.2×—

Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's finance lease, principal payments.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cytokinetics's finance lease, principal payments?: Cytokinetics (CYTK) reported finance lease, principal payments of $0 in Q1 2026.
How has Cytokinetics's finance lease, principal payments changed year-over-year?: Cytokinetics's finance lease, principal payments decreased by 100.0% year-over-year, from $202K to $0.